Reuters

OpenAI must face part of Intercept lawsuit over AI training

Feb 20 - Artificial intelligence giant OpenAI lost a bid on Thursday to dismiss a lawsuit in New York federal court alleging it misused news articles published by The Intercept to train its popular ...
Nasdaq

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
Nasdaq

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

Shares of Intercept Pharmaceuticals, Inc. ICPT soared 79.2% after Italy-based pharmaceutical company Alfasigma S.p.A. announced an agreement to acquire Intercept for $19.00 per share in cash. The ...
Nasdaq

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

Shares of Intercept Pharmaceuticals, Inc. ICPT gained 12.4% in the last six months compared with the industry’s growth of 0.3%. Investors are upbeat on the performance of lead drug Ocaliva and the ...
Business Wire

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...